Amit Chunilal Nathwani
Founder bei Freeline Therapeutics Ltd.
Profil
Amit Chunilal Nathwani has a career history that includes founding positions, current jobs, and education history.
Founding Positions:- Dr. Nathwani is the founder of Freeline Therapeutics Ltd.
(founded in 2015) and holds the title of Director & Chief Scientific Officer.
-.
Dr. Nathwani is the founder of Novalgen Ltd.
(founded in 2019) and holds the title of Chief Executive Officer & Director.
Current Job(s):- Dr. Nathwani is currently working at Royal Free Hospital Medical School since 2012 as the Director-Katharine Dormandy Hemophilia Centre.
-.
Dr. Nathwani is currently working at University College London since 2011 as a Professor.
Education History:- Dr. Nathwani obtained an undergraduate degree from the University of Aberdeen in 1984.
- Dr. Nathwani obtained a doctorate degree from The Open University.
Aktive Positionen von Amit Chunilal Nathwani
| Unternehmen | Position | Beginn |
|---|---|---|
Freeline Therapeutics Ltd.
 Freeline Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Freeline Therapeutics Ltd. operates as a biopharmaceutical company, which develops gene therapies for bleeding and other debilitating disorders. The company was founded by Chris Hollowood in 2015 and is headquartered in London, the United Kingdom. | Founder | 01.01.2015 |
| University College London | Corporate Officer/Principal | 01.11.2011 |
| Royal Free Hospital Medical School | Corporate Officer/Principal | 01.11.2012 |
Novalgen Ltd.
 Novalgen Ltd. BiotechnologyHealth Technology Part of Convergys Capital Ltd., Novalgen Ltd. is a clinical stage immunology company based in Northwood Hills, UK. Novalgen is developing breakthrough immunotherapies for people with immunologically driven diseases using their autoregulation platform. The British company's lead program, NVG-111, is an ROR1-targeting bispecific antibody T-cell engager for the treatment of both hematological malignancies and solid tumors using their breakthrough bispecific antibody technology. The private company's lead AR program, NVG-222, builds on the success of NVG-111 and is primed for entry into the clinic in 2024. The company was founded by Amit Chunilal Nathwani and has been the CEO since incorporation. | Founder | 01.01.2019 |
Ehemalige bekannte Positionen von Amit Chunilal Nathwani
| Unternehmen | Position | Ende |
|---|---|---|
| FREELINE THERAPEUTICS HOLDINGS PLC | Founder | 04.04.2023 |
Ausbildung von Amit Chunilal Nathwani
| University of Aberdeen | Undergraduate Degree |
| The Open University | Doctorate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Private Unternehmen | 3 |
|---|---|
Freeline Therapeutics Ltd.
Freeline Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Freeline Therapeutics Ltd. operates as a biopharmaceutical company, which develops gene therapies for bleeding and other debilitating disorders. The company was founded by Chris Hollowood in 2015 and is headquartered in London, the United Kingdom. | Health Technology |
Freeline Therapeutics Holdings Plc
 Freeline Therapeutics Holdings Plc BiotechnologyHealth Technology Freeline Therapeutics Holdings Plc engages in the business of developing and commercializing gene therapies. It also develops gene therapies for bleeding and other debilitating disorders. The company was founded by Markus Hörer and Amit Chunilal Nathwani in 2015 and is headquartered in Stevenage, the United Kingdom. | Health Technology |
Novalgen Ltd.
Novalgen Ltd. BiotechnologyHealth Technology Part of Convergys Capital Ltd., Novalgen Ltd. is a clinical stage immunology company based in Northwood Hills, UK. Novalgen is developing breakthrough immunotherapies for people with immunologically driven diseases using their autoregulation platform. The British company's lead program, NVG-111, is an ROR1-targeting bispecific antibody T-cell engager for the treatment of both hematological malignancies and solid tumors using their breakthrough bispecific antibody technology. The private company's lead AR program, NVG-222, builds on the success of NVG-111 and is primed for entry into the clinic in 2024. The company was founded by Amit Chunilal Nathwani and has been the CEO since incorporation. | Health Technology |
